Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ensituximab - Precision Biologics

Next Previous
Drug Profile

Ensituximab - Precision Biologics

Alternative Names: NEO-101; NEO-102; NPC-1C

Latest Information Update: 26 Dec 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neogenix Oncology
  • Developer Duke University Medical Center; H. Lee Moffitt Cancer Center and Research Institute; Johns Hopkins Medical Institutions; Montefiore Medical Center; National Cancer Institute (USA); Precision Biologics; University of North Carolina; University of Texas Southwestern Medical Center; Yale University School of Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 19 Dec 2019 Precision Biologics terminates a phase I/II trial in Pancreatic Cancer in USA due to trial futility as per DSMB recommendation (NCT01834235)
  • 02 Aug 2019 Phase II development is ongoing in the US
  • 26 Feb 2018 Ligand Pharmaceuticals, prior to February 2018, acquires the economic rights to certain programmes based on Selexis owned SUREtechnology platform, including the ensituximab programme

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top